News
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
27 Mar 24
Analyst Ratings
Oppenheimer Reiterates Outperform on Catalyst Pharmaceuticals, Maintains $29 Price Target
27 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
22 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
14 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Citigroup Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $27
14 Mar 24
News, Price Target, Initiation, Analyst Ratings
Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available In The U.S. For The Treatment Of Duchenne Muscular Dystrophy
13 Mar 24
Biotech, News, General
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts
7 Mar 24
Analyst Ratings
B of A Securities Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $23
7 Mar 24
News, Price Target, Initiation, Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Catalyst Pharmaceuticals, Raises Price Target to $34
1 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target
1 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Top 3 Health Care Stocks You May Want To Dump In Q1
29 Feb 24
News, Short Ideas, Small Cap, Pre-Market Outlook, Markets, Trading Ideas
Catalyst Pharmaceuticals Q4 Adj. EPS $0.53 Beats $0.26 Estimate, Sales $110.57M Beat $106.12M Estimate
29 Feb 24
Earnings, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Earnings Preview For Catalyst Pharmaceuticals
27 Feb 24
Earnings
Catalyst Pharmaceuticals To Present At MDA Clinical & Scientific Conference Details Of Registry For Study Of Long-Term Safety And Quality Of Life In Duchenne Muscular Dystrophy Patients Treated With AGAMREE
27 Feb 24
Biotech, News, General
Press releases
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
25 Apr 24
Press Releases
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28 Mar 24
News, Press Releases
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
27 Mar 24
News, Press Releases
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
21 Mar 24
Opinion, Press Releases
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
14 Mar 24
Press Releases
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13 Mar 24
Health Care, Press Releases
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
5 Mar 24
News, Press Releases
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
Earnings, News, Health Care, Press Releases
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
27 Feb 24
News, Press Releases
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 Feb 24
News, Press Releases